We look forward to presenting updates for selected #mRNA and #ADC #oncology candidates at the AACR Annual Meeting 2024. This year’s data show how we’re delivering on our commitment of investigating novel treatment approaches to patients. #AACR2024

👉investors.biontech.de/news-releases/…

We presented a positive data update for our #CARTcell therapy candidate BNT211 in advanced solid tumors at ESMO - Eur. Oncology Congress 2023. Our goal is to help improve the outcomes for a broad range of hard-to-treat tumors. Read more about the data update here: investors.biontech.de/news-releases/…

We announced today that the first patient has been treated in a #PDAC Ph2 clinical trial with our individualized #mRNA cancer immunotherapy candidate autogene cevumeran. investors.biontech.de/news-releases/…

We are excited to present updates for five of our clinical candidates across our oncology pipeline at the 2023 ESMO - Eur. Oncology Congress. They underline the potential of our precision medicine toolkit for the treatment of solid tumors with high unmet medical need. investors.biontech.de/news-releases/…

We applaud Katalin Kariko and Drew Weissman on their #NobelPrize in Physiology or Medicine for pioneering nucleoside base modifications which were one of the key innovations applied to our #mRNA -based COVID-19 vaccine. Gratulálunk and congrats!

BioNTech has always been deeply rooted in academia. #STEM grads can now explore #science projects and apply for a full-time contract via our ATLAS #PhD program, a collab with TRON. Students with a sweet spot for #biomedical #research can apply by Oct 31. atlas-phdprogram.com/how-to-apply

We are pleased to announce our strategic partnership with CEPI to advance the development of our #mRNA based BNT166 #vaccine program for the prevention of mpox. investors.biontech.de/news-releases/…

The U.S. FDA just approved our Omicron XBB.1.5-adapted COVID-19 vaccine for individuals 12+ years & granted emergency use for individuals 6 month through 11 years. The updated vaccine will be available at pharmacies, hospitals & clinics across the US soon. investors.biontech.de/news-releases/…

The EU Medicines Agency’ Committee for Medicinal Products for Human Use recommended marketing authorization of our XBB.1.5-adapted #COVID -19 vaccine. Following approval by the EC, the updated vaccine will be ready to ship to applicable EU member states immediately. investors.biontech.de/news-releases/…

#BioNTech expands its Management Board by appointing James Ryan as Chief Legal Officer. James will lead the legal strategy & global legal operations, contributing to BioNTech's success and growth trajectory in its mission to develop innovative #medicines . investors.biontech.de/news-releases/…

We enter H2/2023 with a strong financial position and have submitted applications for a variant adapted #COVID -19 vaccine to authorities. We aim to become a multi-product company by investing in our own clinical programs and adding compounds from partners. investors.biontech.de/news-releases/…

Welcome InstaDeep to BioNTech! The acquisition supports our strategy, aiming to build world-leading capabilities in #AI -driven drug discovery and development of next-gen #immunotherapies and vaccines to address diseases with high unmet medical need. investors.biontech.de/news-releases/…

We are pleased to be an integral part of this long-term partnership. First patients are expected to be treated in 2023 with the majority being enrolled from 2026+. We aim to improve outcomes for patients and broaden access to innovative immunotherapies in the UK and worldwide.

Today, the first patient has been treated in a pivotal Ph3 trial evaluating our antibody candidate BNT316/ONC-392 in #NSCLC , jointly developed with OncoC4. We are committed to rapidly advancing our #oncology pipeline towards late-stage development. investors.biontech.de/news-releases/…

We have concluded our AGM 2023. Baroness Nicola Blackwood will succeed Christoph Huber on the Supervisory Board. Michael Motschmann & Ulrich Wandschneider have been reappointed. investors.biontech.de/news-releases/…

In Q1/2023, we expanded our toolkit of cutting-edge technologies to new modalities and added novel oncology candidates to our pipeline. Our aim is to provide therapeutic benefits for cancer patients along the entire treatment journey. investors.biontech.de/news-releases/…